Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.
Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.
Arlene Siefker-Radtke, MD,...